Get the Stockscreener App
1.46
20.66%
0.25
Dermata Therapeutics Inc stock is traded at $1.46, with a volume of 39.28M.
It is up +20.66% in the last 24 hours and up +8.15% over the past month.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.
See More
Previous Close:
$1.21
Open:
$1.49
24h Volume:
39.28M
Relative Volume:
15.37
Market Cap:
$4.14M
Revenue:
-
Net Income/Loss:
$-8.85M
P/E Ratio:
-0.0898
EPS:
-16.2673
Net Cash Flow:
$-9.34M
1W Performance:
+22.69%
1M Performance:
+8.15%
6M Performance:
-73.11%
1Y Performance:
-87.63%
1-Day Range:
$1.37
$1.84
1-Week Range:
$1.165
$1.84
52-Week Range:
$1.11
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.46 | 4.14M | 0 | -8.85M | -9.34M | -16.27 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Dermata Therapeutics Ramps Up Skincare Division with New VP Appointment - StocksToTrade
Dermata’s Strategic Pivot: New Skincare Line on the Horizon - timothysykes.com
Dermata Gears Up For First Once-Weekly Acne Kit Launch, Eyeing A Slice Of $3.8B Market - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-20 05:04:24 - baoquankhu1.vn
Dermata Therapeutics (DRMAW) Expected to Announce Earnings on Wednesday - Defense World
Dermata Therapeutics (DRMA) SVP adds 1,000 shares in insider buy - Stock Titan
CEO Change: Whats the outlook for Dermata Therapeutics Incs sectorQuarterly Profit Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Dermata Therapeutics Inc expected to post a loss of $1.54 a shareEarnings Preview - TradingView
Dermata Therapeutics names Kyra Peckaitis VP of marketing By Investing.com - Investing.com Canada
Dermata Therapeutics names Kyra Peckaitis VP of marketing - Investing.com Nigeria
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing - lincolnjournal.com
New Dermata marketing chief to launch Tome skincare line in 2026 - Stock Titan
Retail Surge: Is Dermata Therapeutics Inc Equity Warrant a strong candidate for buy and holdJuly 2025 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
Exit Recap: Is Dermata Therapeutics Inc a momentum stockMarket Volume Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Dermata Therapeutics Launches Tome Skincare Line to Address Daily Skin Health Needs - geneonline.com
Dermata Opens a New Chapter with the Release of Tome Skincare - standard-journal.com
Once‑weekly acne treatment at home: Dermata’s new Tome skincare line - Stock Titan
DRMA SEC FilingsDermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Wall Street Zen Upgrades Dermata Therapeutics (NASDAQ:DRMA) to Hold - Defense World
Dermata Therapeutics Announces Board Resignation and Size Reduction - TipRanks
Board shakeup at Dermata (DRMA) as director Mary Fisher plans exit - Stock Titan
ARMISTICE CAPITAL, LLC Reduces Stake in Dermata Therapeutics Inc - GuruFocus
Update Report: Will Dermata Therapeutics Inc benefit from seasonalityPortfolio Performance Report & Weekly Return Optimization Alerts - baoquankhu1.vn
DRMAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Large Dermata (DRMA) holder Gerald Proehl reports 17.3% ownership stake - Stock Titan
Growth Value: What is Dermata Therapeutics Incs valuation compared to sector2025 Winners & Losers & Technical Pattern Alert System - baoquankhu1.vn
Contrasting Qiagen (NYSE:QGEN) & Dermata Therapeutics (NASDAQ:DRMA) - Defense World
Chipmakers Recap: Can Dermata Therapeutics Inc Equity Warrant grow without external fundingJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Growth Recap: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Growth Report & Low Drawdown Trading Techniques - baoquankhu1.vn
Market Movers | Winners: ADVB, KNRX, DRMA | Losers: MBRX, ALIT, DBGI - Trefis
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Armistice Capital, Steven Boyd disclose 4.99% stake in Dermata (DRMA) - Stock Titan
ACXP PE Ratio & Valuation, Is ACXP Overvalued - Intellectia AI
Can Dermata Therapeutics Inc. expand into new markets2025 AllTime Highs & Verified Technical Trade Signals - mfd.ru
Can Dermata Therapeutics Inc. Equity Warrant stock double in the next yearWeekly Market Summary & AI Powered Market Trend Analysis - mfd.ru
How rising interest rates impact Dermata Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - mfd.ru
HSDT PE Ratio & Valuation, Is HSDT Overvalued - Intellectia AI
DRMA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DRMA Should I Buy - Intellectia AI
Bristol Investment Fund Ltd. v. Dermata Therapeutics Inc.: Complaint (‘$160K Breach of Contract’) - OffshoreAlert
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Will Dermata Therapeutics Inc. stock benefit from AI adoption2025 Momentum Check & AI Forecasted Entry/Exit Points - mfd.ru
Stock Report: Should I average down on Dermata Therapeutics Inc Equity Warrant stockJuly 2025 Short Interest & Real-Time Buy Signal Notifications - baoquankhu1.vn
Surprises Report: What are Twin Hospitality Group Incs technical support levels - baoquankhu1.vn
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):